Plant Name: Jagera pseudorhus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 3.929E-09 | 8.556E-06 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 2.332E-07 | 2.207E-04 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.780E-07 | 3.589E-04 | FABP3, FFAR1, PPARG, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.053E-06 | 1.208E-03 | FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0008283; cell proliferation | GO:0048660; regulation of smooth muscle cell proliferation | 3.148E-06 | 1.672E-03 | HPGD, PPARD, PPARG, TERT |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 4.370E-06 | 2.213E-03 | FABP3, PPARA, PPARG, TLR2 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 6.423E-06 | 3.108E-03 | PPARA, PPARG |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 8.394E-06 | 3.655E-03 | PPARA, PPARD, PPARG |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 9.631E-06 | 3.813E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 9.631E-06 | 3.813E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 9.631E-06 | 3.813E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 9.631E-06 | 3.813E-03 | FABP3, PPARG |
| MF | Unclassified; | GO:0004872; receptor activity | 1.239E-05 | 4.733E-03 | FFAR1, FFAR4, HPGD, PPARA, PPARD, PPARG, TLR2, TSHR |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.343E-05 | 4.958E-03 | FABP3, LMNA, PPARD, PPARG, TERT, TLR2 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.474E-05 | 5.260E-03 | PPARA, PPARD, PPARG |
| MF | GO:0060089; molecular transducer activity | GO:0004955; prostaglandin receptor activity | 2.884E-05 | 8.721E-03 | HPGD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 3.286E-05 | 9.669E-03 | ALOX15, PPARA, PPARD |
| BP | GO:0032502; developmental process | GO:0032502; developmental process | 3.494E-05 | 9.834E-03 | ALOX15, FABP4, FABP5, FFAR4, HPGD, LMNA, PPARA, PPARD, PPARG, TERT, TLR2, TSHR |
| BP | GO:0008152; metabolic process | GO:1902894; negative regulation of pri-miRNA transcription from RNA polymerase II promoter | 3.523E-05 | 9.834E-03 | PPARA, PPARD |
| BP | GO:0051179; localization | GO:0060099; regulation of phagocytosis, engulfment | 3.523E-05 | 9.834E-03 | ALOX15, PPARG |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Cancer | C00-C96 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TLR2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; TLR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PPARG; PPARG |